Newer topical therapies for the treatment of acne vulgaris

Cutis

Volumn 80, Issue 5, 2007, Pages 400-410

  Del Rosso, James Q ^a  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN; DAPSONE; KERATOLYTIC AGENT; RETINOIC ACID;

ACNE VULGARIS; DRUG COMBINATION; HUMAN; REVIEW; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS; CLINDAMYCIN; DAPSONE; DRUG COMBINATIONS; HUMANS; KERATOLYTIC AGENTS; TREATMENT OUTCOME; TRETINOIN;

EID: 37049008664     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
2. Strauss JS, Krowchuk DP, Leyden JJ, et al, American Academy of Dermatology/American Academy of Dermatology Association. Guidelines for care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651-663.
3. Hall RP, Mickle CP. Dapsone. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia, Pa: Saunders; 2007:239-257.
4. Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone: a possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest. 1978;62:214-220.
5. Prendiville JS, Logan RA, Russell-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clin Exp Dermatol. 1988;13:67-71.
6. Thiboutot D, Sharata H, Taylor S, et al. Pharmacokinetics of dapsone topical 5% gel demonstrate minimal systemic exposure. Poster presented at: American Academy of Dermatology 63rd Annual Meeting; February 18-22, 2005; New Orleans, La. P140.
7. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56:439-447.
8. Fleischer AB Jr, Abramovits W, Pariser DM, et al. Dapsone gel, 5% in combination with adapalene gel, 0.1%, benzoyl peroxide, 4%, or vehicle gel for treatment of acne vulgaris: a randomized, double-blind study. Poster presented at: American Academy of Dermatology 65th Annual Meeting; February 2-6, 2007; Washington, DC. P113.
9. Taylor S, Raimer S, Lucky AW. Dapsone gel 5% is effective and safe for the treatment of acne vulgaris in adolescent patients. Poster presented at: American Academy of Dermatology 64th Annual Meeting; March 3-7, 2006; San Francisco, Calif. P150.
10. Data on file. Dermal safety studies with dapsone 5% gel. Vancouver, Canada: QLT Inc; 2005.
11. Schlessinger J, Menter A, Gold M, et al, Ziana Study Group. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6:607-615.
12. Leyden JJ, Wortzman M, Plott T. Safety of a novel gel formulation of 0.025% tretinoin and 1.2% clindamycin phosphate: results from a 52-week open-label study. Poster presented at: 31st Hawaii Dermatology Seminar; March 4-9, 2007; Maui, Hawaii.
13. Leyden JJ, Plott T, Wortzman M. A novel gel formulation of 0.025% tretinoin and 1.2% clindamycin phosphate: efficacy in patients with mild, moderate, and severe baseline acne. Poster presented at: 31st Hawaii Dermatology Seminar; March 4-9, 2007; Maui, Hawaii.
14. Plott RT. Unique aqueous formulation results in reduced risk of tretinoin-induced irritation. Poster presented at: American Academy of Dermatology 65th Annual Meeting; February 2-6, 2007; Washington, DC. P132.
15. Leyden JJ, Plott T, Wortzman M. A novel gel formulation of tretinoin and clindamycin is not associated with retinoid induced flaring of inflammatory acne. Poster presented at: Hawaii Dermatology Seminar; March 4-9, 2007; Maui, Hawaii.